HNSPF (Hansoh Pharmaceutical Group Co) EPS without NRI: $0.13 (TTM As of Dec. 2025)


HNSPF Hansoh Pharmaceutical Group Co Ltd HNSPF
92 GF Score
Price $3.83
GF Value $3.64
Valuation Fairly Valued
View Full Analysis

What is Hansoh Pharmaceutical Group Co EPS without NRI?

Hansoh Pharmaceutical Group Co HNSPF 92 EPS without NRI is $0.13 as of Dec. 2025. GuruFocus rates HNSPF with a GF Score™ of 92/100 and a GF Value™ of $3.64 (Fairly Valued). Among 786 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 75.45% on this metric.

Hansoh Pharmaceutical Group Co's earnings per share without non-recurring items for the six months ended in Dec. 2025 was $0.06. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $0.13.

During the past 12 months, Hansoh Pharmaceutical Group Co's average earnings per share (NRI) Growth Rate was 33.60% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 29.10% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 14.70% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Hansoh Pharmaceutical Group Co's EPS without NRI or its related term are showing as below:

HNSPF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -2.6   Med: 13.3   Max: 29.1
Current: 29.1

During the past 10 years, Hansoh Pharmaceutical Group Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 29.10% per year. The lowest was -2.60% per year. And the median was 13.30% per year.

HNSPF's 3-Year EPS without NRI Growth Rate is ranked better than
75.45% of 786 companies
in the Drug Manufacturers industry
Industry Median: 9.6 vs HNSPF: 29.10

Hansoh Pharmaceutical Group Co's EPS (Diluted) for the six months ended in Dec. 2025 was $0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.13.

Hansoh Pharmaceutical Group Co's EPS (Basic) for the six months ended in Dec. 2025 was $0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.13.


Hansoh Pharmaceutical Group Co  (OTCPK:HNSPF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Hansoh Pharmaceutical Group Co EPS without NRI Related Terms


Hansoh Pharmaceutical Group Co EPS without NRI Historical Data

* Premium members only.

The historical data trend for Hansoh Pharmaceutical Group Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansoh Pharmaceutical Group Co EPS without NRI Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.06 0.07 0.10 0.13

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.06 0.04 0.08 0.06

HNSPF vs ZTS, UTHR: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's PE Ratio without NRI falls into.


HNSPF
92GF Score
Hansoh Pharmaceutical Group Co Ltd HNSPF
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansoh Pharmaceutical Group Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $0.13 mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a EPS without NRI of $0.13 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Hansoh Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #193 out of 786 companies in the Drug Manufacturers industry, placing it in the top 24.6%.
Is Hansoh Pharmaceutical Group Co's EPS without NRI too high?
Hansoh Pharmaceutical Group Co's current EPS without NRI is $0.13. The Drug Manufacturers industry median EPS without NRI is 9.60. Hansoh Pharmaceutical Group Co's value of $0.13 is 98.6% below this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #193 out of 786 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #193 out of 786 companies for EPS without NRI. This places Hansoh Pharmaceutical Group Co in the top 25% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.60. Hansoh Pharmaceutical Group Co's value of $0.13 is 98.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current EPS without NRI of $0.13 is 98.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current EPS without NRI is $0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Fairly Valued. The stock's GF Value™ is $3.64, compared to a current price of $3.83 — trading 5.1% above its estimated fair value. The current EPS without NRI is $0.13 and 98.6% below the Drug Manufacturers industry median of 9.60. Hansoh Pharmaceutical Group Co's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current EPS without NRI is $0.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued. The current stock price of $3.83 is trading 5.1% above its estimated GF Value™ of $3.64. GuruFocus considers Hansoh Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for HNSPF:

  • EPS without NRI: $0.13
  • GF Value™: $3.64 vs. price of $3.83 (5.1% above fair value)
  • GF Score™: 92/100
  • Industry Position: 98.6% below the Drug Manufacturers median (#193 of 786)

No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansoh Pharmaceutical Group Co Business Description

Address No. 287 Xiangke Road, Pudong New Area, Shanghai, CHN
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
92GF Score

Get the complete analysis for HNSPF

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.83
Price
$3.64
GF Value